Skip to main content

Usana Health Sciences Value Stock - Dividend - Research Selection

Usana health sciences

ISIN: US90328M1071 , WKN: 923145

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

General

 

USANA Health Sciences, Inc., a Utah corporation, was founded in 1992 by Myron W. Wentz, Ph.D. We develop and manufacture high-quality, science-based nutritional and personal care products with a primary focus on promoting long-term health and reducing the risk of chronic degenerative disease. In so doing, we are committed to continuous product innovation and sound scientific research. We have operations in 19 markets worldwide, where we distribute and sell our products by way of direct selling. We have chosen this distribution method as we believe it is the most conducive to meeting our vision as a company, which is improving the overall health and nutrition of individuals and families around the world. Our net sales in fiscal year 2014 were $790.5 million, of which 81.8% were in markets outside of the United States. As a U.S.-based multi-national company with an expanding international presence, our operating results are sensitive to currency fluctuations, as well as economic and political conditions in markets throughout the world. Additionally, we are subject to the various laws and regulations in the United States, China, and the other markets in which we operate with respect to the products that we sell and to our method of distribution.

 

Our customer base comprises two types of customers: "Associates" and "Preferred Customers." Associates share in our company vision by acting as independent distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase our products strictly for personal use and are not permitted to resell or to distribute the products. As of January 3, 2015, we had 349,000 active Associates and 81,000 active Preferred Customers worldwide.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


FSTA: Consumer Staples Dashboard For October

2025-10-16
Discover top-rated consumer staples stocks and ETFs with strong value scores. Click for more on the Fidelity MSCI Consumer Staples Index ETF (FSTA).

USANA's Vitamin D Supplement Shines Bright with ConsumerLab.com Seal of Approval--Setting the Standard for Product Quality

2025-10-16
USANA (NYSE:USNA), a global leader in cellular nutrition, is bringing a little more sunshine to wellness. Its top-rated Vitamin D supplement has officially earned the prestigious ConsumerLab.com Seal of Approval—a recognition reserved for products that deliver on purity, potency, and scientific precision. With approximately 42% of adults in the United States considered vitamin D deficient, having a vitamin D supplement on the market you can trust makes all the difference.

USANA Health Sciences (USNA) Is Down 25.4% After Weak Q3 Outlook and Compensation Plan Impact—What’s Changed

2025-10-13
Recently, USANA Health Sciences announced preliminary third-quarter results that missed expectations, with the company anticipating a net loss of US$6.5 million compared to a profit a year earlier. This reflects the impact of a new Brand Partner compensation plan and weaker Hiya direct-to-consumer sales, both of which contributed to a sharper slowdown in sales and productivity. We’ll examine how the new compensation plan’s effect on sales momentum could alter the company’s investment outlook...

USANA Q3 2025 Preview: Short-Term Challenges Amid Strategic Transition

2025-10-13
USANA faces short-term challenges from profitability declines and business shifts despite solid sales and no debt. Find out why USNA stock is a Hold.

USANA Health Sciences (USNA): Assessing Valuation After Surprising Q3 Loss and Strategic Setbacks

2025-10-11
USANA Health Sciences saw its stock drop sharply after revealing preliminary third-quarter results that were well below expectations. The company reported a net loss as it faces slower sales and challenges related to recent strategic changes. See our latest analysis for USANA Health Sciences. The sharp 22.8% single-day share price drop is just the latest in a series of heavy declines for USANA Health Sciences this year. After a string of negative surprises and a tougher operating environment,...

Sector Update: Health Care Stocks Decline Late Afternoon

2025-10-10
Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index down 1.4% and t

Why USANA (USNA) Shares Are Trading Lower Today

2025-10-10
Shares of health and wellness products company USANA Health Sciences (NYSE:USNA) fell 20.7% in the afternoon session after the company announced preliminary third-quarter results that fell below expectations, signaling a sharp decline in profitability.

Sector Update: Health Care Stocks Decline Friday Afternoon

2025-10-10
Health care stocks were lower Friday afternoon, with the NYSE Health Care Index and the Health Care

1 of Wall Street’s Favorite Stock Worth Your Attention and 2 We Find Risky

2025-10-10
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

USANA Health Sciences Provides Preliminary Third Quarter Results

2025-10-09
SALT LAKE CITY, October 09, 2025--USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary results for the third quarter ended September 27, 2025. The Company anticipates third quarter 2025 net sales will be approximately $214 million, which compares with $200 million in the prior-year period. Earnings from operations are expected to be $1.2 million for the current-year quarter, or 0.6% of net sales, as compared to $15.6 million in the third quarter of 2024.